360Dx

Oncgnostics Licenses Epigenetics-Based Cervical Cancer Test to Chinese Firm

Apr 11, 2017

NEW YORK (GenomeWeb) – Oncgnostics, a Jena, Germany-based molecular diagnostic company, has out-licensed its GynTect cervical cancer test to Changchun Jienuo Medical Technology (CJMT), a subsidiary of Sinopharm Group in China.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Menu

Oncgnostics Licenses Epigenetics-Based Cervical Cancer Test to Chinese Firm

To read the full story....

Breaking News

Pro-Lab Diagnostics Nabs FDA Emergency Use Authorization for Molecular SARS-CoV-2 Test

HHS Invests $6.5M in Aegis Sciences, Sonic Healthcare USA to Expand Coronavirus Testing Capacity

Myriad Genetics Q4 Revenues Plummet 57 Percent on Coronavirus Pandemic Pressures

Progenity Q2 Revenues Fall 70 Percent in First Earnings Report Since IPO

In Brief This Week: Thermo Fisher Scientific, Quanterix, BGI, Illumina, and More

Aspira Q2 Revenues Down 32 Percent

COVID-19 Wastewater-Based Epidemiology: Methods and Insights for SARS-CoV-2 Community Surveillance

Case Study: An IVD Manufacturer’s Experience Building a Complete Sample-to-Result Workflow

What's Popular?

Many Initiatives Turning to RT-LAMP as Alternative to PCR for Rapid COVID-19 Screening Assays

HHS Invests $6.5M in Aegis Sciences, Sonic Healthcare USA to Expand Coronavirus Testing Capacity

Pro-Lab Diagnostics Nabs FDA Emergency Use Authorization for Molecular SARS-CoV-2 Test

Biomeme, LumiraDx PCR Coronavirus Tests Get FDA Emergency Use Authorization

Solaris Diagnostics, Alpha Genomix Coronavirus Tests Get FDA Emergency Use Authorization

Sponsorships